Green Thumb Industries (OTCMKTS:GTBIF – Get Free Report) and Delcath Systems (NASDAQ:DCTH – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
Volatility and Risk
Green Thumb Industries has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
Valuation and Earnings
This table compares Green Thumb Industries and Delcath Systems”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Green Thumb Industries | $1.18 billion | 1.11 | $114.15 million | $0.54 | 12.34 |
| Delcath Systems | $85.23 million | 6.26 | $2.70 million | $0.01 | 1,538.00 |
Green Thumb Industries has higher revenue and earnings than Delcath Systems. Green Thumb Industries is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Green Thumb Industries and Delcath Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Green Thumb Industries | 10.48% | 6.03% | 4.09% |
| Delcath Systems | 0.56% | 0.46% | 0.42% |
Insider and Institutional Ownership
0.1% of Green Thumb Industries shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 9.4% of Green Thumb Industries shares are owned by insiders. Comparatively, 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Green Thumb Industries and Delcath Systems, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Green Thumb Industries | 0 | 1 | 1 | 1 | 3.00 |
| Delcath Systems | 0 | 1 | 5 | 1 | 3.00 |
Green Thumb Industries currently has a consensus price target of $18.00, suggesting a potential upside of 170.07%. Delcath Systems has a consensus price target of $23.17, suggesting a potential upside of 50.63%. Given Green Thumb Industries’ higher probable upside, analysts clearly believe Green Thumb Industries is more favorable than Delcath Systems.
Summary
Green Thumb Industries beats Delcath Systems on 8 of the 13 factors compared between the two stocks.
About Green Thumb Industries
Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, capsules, tinctures, edibles, topicals, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM brands. It distributes its products primarily to third-party retail customers and sells finished products directly to consumers in its own retail stores, as well as direct-to consumer delivery channel. Green Thumb Industries Inc. was founded in 2014 and is headquartered in Chicago, Illinois.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Receive News & Ratings for Green Thumb Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Green Thumb Industries and related companies with MarketBeat.com's FREE daily email newsletter.
